At my initial diagnosis I participated in a clinical trial evaluating Herceptin, a so-called personalized medicine (PM) drug targeting a mutation believed to be driving my cancer.
The new Redditch and Bromsgrove Clinical Commissioning Group (RBCCG) takes over in April and has started "initial discussions" with University Hospitals Birmingham NHS Foundation Trust, Birmingham Women's NHS Foundation Trust and Birmingham Children's NHS Foundation Trust.